



18-05-2023

To,
The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Symbol: SAKAR

SUB: Sakar has entered into a contract for ONE PATENTED& SECOND INOVATIVE ONCOLOGY PRODUCTS development and supply with NDDS for Switzerland based Ferring Pharmaceuticalsand Bazell Pharma

Reference: Announcement under Regulation 30 (LODR)

Dear All,

It gives us immense pleasure to share that Sakar Healthcare Ltd. has entered into an agreement this consecutive week with the Swiss pharmaceutical major- Ferring Pharmaceuticals Pvt. Ltd. and Bazell Pharma LLP for developing the novel drug delivery system (NDDS) for two of the oncology products. Both the products are prescription medicine in segment of oncology- one is androgen biosynthesis inhibitors while the other being first triple-acting, androgen receptor antagonist. Both are extensively used to treat Prostate cancer- while the patented one in liquid sachet is for prostate cancer that has metastasized, the other innovative one in sachet powder is to block testosterone to reach prostate cancer cells. The present worldwide market size for general prostate therapeutics is USD 12.12 billion, expected to be USD 21.48 billion by 2030- with a CAGR of 8.4%. With these patented and innovative newly developed drug delivery for two products Ferring has planned to grab a major global market share in the category (Ref: Grand View Research, Report ID: GVR-1-68038-925-8).


Sakar has initiated for the development of the product and scale up batches at its research-driven API-integrated oncology formulation-manufacturing unit at Bavla, near Ahmedabad, Gujarat, India. The initial outcomes are quite encouraging to progress to the advance stage of manufacturing. No sooner the products get regulatory nod, Ferring-Bazell aspires to take both products manufactured at Sakar's modern oncology facility to all corners of the world.

This back-to-back contract confirms Sakar's capabilities towards product development, process optimization, technology management skills, analytical documentation with cytotoxic products that helped perceive concept towards delivery of products, with exclusive worldwide supply.

This is for your information, records and meeting the disclosure requirements under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Thanking you,

Yours faithfully,
for **SAKAR HEALTHCARE LIMITED**


BHARAT SONI
COMPANY SECRETARY &
COMPLIANCE OFFICER

